Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Reports Q2 2024 Financial Results and Corporate Updates
Summary
Terns Pharmaceuticals, Inc. reported its financial results for the quarter ended June 30, 2024, showing a net loss of $22.7 million. The company's cash position stood at $225.3 million as of June 30, 2024, which is expected to support its operations into 2026. Terns also provided updates on its clinical pipeline, with top-line data from the Phase 1 trial of TERN-601 for obesity expected in September 2024 and interim data from the Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia expected in December 2024. The company also announced changes in its executive team, including the appointment of Elona Kogan as Chief Legal Officer and the upcoming departure of Bryan Yoon, Chief Operating Officer.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement